How do we sleep? Towards physical requirements for space and environment while travelling.

To establish guidelines for sleeping space in vehicles, the sleeping postures of 189 participants are studied, 105 of them were asked to take the position in which they fall asleep and 84 have been asked to assume the position in which they lie most of the time. Seven percent slept on the stomach, 19% on the back and 74% on the side and 49% slept on the side with both legs flexed. For all participants a bed size of 200 × 90 cm will do.

Modeling passenger comfort in turboprop aircraft using objective measures.

Background: A quantitative comfort model will aid in evaluating comfort levels of various target groups before the actual flight of an airplane. However, constructing the model is always a challenge due to the complexity of the phenomenon.

Objectives: In this paper, we present quantitative comfort models to predict the (dis)comfort of passengers flying with turboprops based on objective measures.

Does a reclined backrest with less legroom meet the same comfort as a fixed backrest with 80 mm more leg room?

Background: In vehicles there is often limited space for seats. This might mean that reclining the back rest reduces the legroom. The second row in a cargo van has this problem and in this limited space an upright seat and a reclined seat with less legroom was developed and tested.

2D and 3D Self-Assembly of Fluorine-Free Pillar-[5]-Arenes and Perfluorinated Diacids at All-Aqueous Interfaces.

The interaction of perfluorinated molecules, also known as "forever chemicals" due to their pervasiveness, with their environment remains an important yet poorly understood topic. In this work, the self-assembly of perfluorinated molecules with multivalent hosts, pillar-[5]-arenes, is investigated. It is found that perfluoroalkyl diacids and pillar-[5]-arenes rapidly and strongly complex with each other at aqueous interfaces, forming solid interfacially templated films.

Anti-citrullinated histone monoclonal antibody CIT-013, a dual action therapeutic for neutrophil extracellular trap-associated autoimmune diseases.

Neutrophil extracellular traps (NETs) contribute to the pathophysiology of multiple inflammatory and autoimmune diseases. Targeting the NETosis pathway has demonstrated significant therapeutic potency in various disease models. Here, we describe a first-in-class monoclonal antibody (CIT-013) with high affinity for citrullinated histones H2A and H4, which inhibits NETosis and reduces tissue NET burden with significant anti-inflammatory consequences.